Chiesi today announces MHRA approval in the UK of Clenil Modulite (beclometasone; 100mcg and 200mcg) formulated with a non-PFAS, low-GWP, next generation propellant (HFA-152a). These are the first pMDIs to use HFA-152a worldwide, with the UK being the first country to approve these products. Chiesi’s propellant transition is expected to cut the carbon footprint of their beclometasone products by up to 90% versus the current propellant and aims to ensure continuity of care for patients by preserving device choice while addressing the environmental impact of these pMDIs.

Read more here: https://www.chiesi.uk.com/media/press-releases/2026-07-21-clenil-mhra-approval
 

Discover how we’re transforming respiratory care for people and the planet: Air | Chiesi Farmaceutici S.p.A.